Secondary histiocytic sarcoma with BRAF^V600E mutation responsive to MAPK-targeted therapy presenting with recurrence with mTOR mutation responsive to mTOR-targeted therapy

Pediatr Blood Cancer. 2021 Oct;68(10):e29166. doi: 10.1002/pbc.29166. Epub 2021 Jun 1.

Authors

Vinayak Venkataraman¹, Lucas R Massoth², Ryan J Sullivan³, Alison M Friedmann⁴

Affiliations

¹ Departments of Medicine and Pediatrics, Massachusetts General Hospital, Boston, Massachusetts, USA.
² Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA.
³ Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
⁴ Department of Pediatrics, Massachusetts General Hospital, Boston, Massachusetts, USA.

PMID: 34061432
DOI: 10.1002/pbc.29166

No abstract available

Publication types

Letter
Comment

MeSH terms

Histiocytic Sarcoma* / drug therapy
Histiocytic Sarcoma* / genetics
Humans
Mutation
Proto-Oncogene Proteins B-raf / genetics
Sarcoma*
TOR Serine-Threonine Kinases / genetics

Substances

MTOR protein, human
BRAF protein, human
Proto-Oncogene Proteins B-raf
TOR Serine-Threonine Kinases